gsk649868
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00426816)
Timeline
Indications
Mechanism of action
- Orexin receptor 2ANTAGONIST
HCRTR2 antagonist
- Orexin receptor 1ANTAGONIST
HCRTR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(-c2ccc(F)cc2)s1- Mol. weight
- 477.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1272307 ↗
Also known as
- (14c)sb649868
- (14c)sb 649868
- (14c)sb-649868
- gsk649868
- gsk649868
- n-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide
- sb649868
- sb649868
- sb649868
- sb 649868
- sb-649868
- sb-649868
- sb-649868
- sb-649868
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01299597 | Phase 1 | Jan 1, 2010 | GlaxoSmithKline |
| NCT01030939 | Phase 1 | Aug 27, 2009 | GlaxoSmithKline |
| NCT00534872 | Phase 1 | Oct 1, 2007 | GlaxoSmithKline |
| NCT00495274 | Phase 1 | Jul 1, 2007 | GlaxoSmithKline |
| NCT00520663 | Phase 1 | Jun 1, 2007 | GlaxoSmithKline |
| NCT00495729 | Phase 1 | Apr 1, 2007 | GlaxoSmithKline |
| NCT00440323 | Phase 1 | Jan 1, 2007 | GlaxoSmithKline |
| NCT00426816 | Phase 2 | Dec 1, 2006 | GlaxoSmithKline |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 8 | 8 | 2 | 2006 |
1 organizations
Page 1 / 1